Journal of Nanomedicine & Nanotechnology

Shubhadeep Banerjee

Publications

• Review Article
  Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy
  Author(s): Raghavendra Gowda, Nathan R. Jones, Shubhadeep Banerjee and Gavin P. RobertsonRaghavendra Gowda, Nathan R. Jones, Shubhadeep Banerjee and Gavin P. Robertson
  
  Therapeutic agents that inhibit a single target often cannot combat a multifactorial disease such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications such as the development of resistance. There are two predominant types of MTIs, (a) single drug inhibitor (SDIs) that affect multiple pathways simultaneously, and (b) combinatorial agents or multi-drug inhibitors (MDIs) that inhibit multiple pathways. Single agent multi-target kinase inhibitors are amongst the most prominent class of compounds belonging to the former, whereas the latter includes many different classes of combinatorial agents that have been used to achieve synergistic efficacy against cancer. Safe delivery and accumulation at the tumor site is of paramount importance for MTIs because inhibition of multiple key signaling pathways has the potential to lead to systemic toxicity. For this re.. View More»
  DOI: 10.4172/2157-7439.1000184

  Abstract PDF